Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement?
Overview
Authors
Affiliations
Background: Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).
Aim: The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.
Methods: Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.
Results: Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).
Conclusions: Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
GERD: Latest update on acid-suppressant drugs.
Al-Frejat Z, Martini N, Esper A, Al-Frejat D, Younes S, Hanna M Curr Res Pharmacol Drug Discov. 2024; 7:100198.
PMID: 39282236 PMC: 11393603. DOI: 10.1016/j.crphar.2024.100198.
A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.
Zhang N, Han M, Zheng Q, Zhang M, Zhi W, Li J Front Pharmacol. 2024; 15:1393526.
PMID: 39139634 PMC: 11319146. DOI: 10.3389/fphar.2024.1393526.
Jeong Y, Lee B, Han S J Clin Med. 2024; 13(11).
PMID: 38892973 PMC: 11172701. DOI: 10.3390/jcm13113262.
Begg M, Tarhuni M, Fotso M, Gonzalez N, Sanivarapu R, Osman U Cureus. 2023; 15(8):e44341.
PMID: 37779765 PMC: 10538946. DOI: 10.7759/cureus.44341.
Long-term potassium-competitive acid blockers administration causes microbiota changes in rats.
Najah H, Edelmuth R, Riascos M, Grier A, Al Asadi H, Greenberg J Surg Endosc. 2023; 37(10):7980-7990.
PMID: 37452210 DOI: 10.1007/s00464-023-10269-6.